Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
...
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 111
- Registration Number
- NCT02097004
- Locations
- 🇰🇷
Seoul National University, Seoul, Korea, Republic of
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT02065336
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong
🇭🇰Queen Mary Hospital, Pokfulam, Hong Kong
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 606
- Registration Number
- NCT01943617
- Locations
- 🇨🇳
302 Military Hospital Of China, Beijing, Beijing, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT01938781
- Locations
- 🇨🇳
Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT01938820
- Locations
- 🇨🇳
Peking University, Beijing, Beijing, China
🇨🇳The Hospital Affiliated to Logistics University of Chinese People's Armed Police Force, Tianjin, Tianjin, China
🇨🇳Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China
A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir
- Conditions
- Interventions
- First Posted Date
- 2013-08-08
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 36
- Registration Number
- NCT01918631
- Locations
- 🇭🇰
Prince of Wales Hospital, Hong Kong, Hong Kong
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
- Conditions
- Interventions
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 82
- Registration Number
- NCT01914744
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2015-08-17
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 105
- Registration Number
- NCT01906580
- Locations
- 🇨🇳
Research Center for Biological Therapy, The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China
Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients
- Conditions
- Interventions
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 115
- Registration Number
- NCT01907230
- Locations
- 🇨🇳
Division of Gastroenterology & Division of Allergy Immunology and Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan
Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA
- Conditions
- Interventions
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2013-10-01
- Target Recruit Count
- 74
- Registration Number
- NCT01892241
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.